FA
ARKG icon

Fagan Associates’s ARK Genomic Revolution ETF ARKG Stock Holding History

Fagan Associates’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-36,171
Closed -$2.7M – 127
2021
Q3 		$2.7M Sell
36,171
-17,873
-33% -$1.5M 0.59% 49
2021
Q2 		$5M Buy
54,044
+4,798
+10% +$408K 1.07% 28
2021
Q1 		$4.37M Sell
49,246
-229
-0.5% -$22.7K 1.02% 29
2020
Q4 		$4.61M Buy
49,475
+12,943
+35% +$1.03M 1.16% 26
2020
Q3 		$2.33M Buy
36,532
+24,792
+211% +$1.45M 0.67% 43
2020
Q2 		$612K Buy
+11,740
New +$504K 0.2% 72
2020
Q1 		– Sell
-6,766
Closed -$227K – 102
2019
Q4 		$227K Buy
+6,766
New +$215K 0.07% 113

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Fagan Associates's ARKG Position: Q4 2021 in Review

Fagan Associates sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 36,171 shares — an estimated $2.7M sold.

Fagan Associates first reported a position in ARKG in Q4 2019 and held it in 7 quarters. The position peaked at $5M in Q2 2021. 461 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Fagan Associates reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Fagan Associates sold 36,171 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $2.7M.
  • Fagan Associates first reported a position in ARK Genomic Revolution ETF in Q4 2019 and held it in 7 quarters.
  • Fagan Associates's ARK Genomic Revolution ETF position peaked at $5M in Q2 2021.
  • 461 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Fagan Associates's 13F filing for Q4 2021, filed 8 Feb 2022.